• Agomab reports results from Phase 1 study of AGMB-447 inhaled ALK5 inhibitor

  Agomab Therapeutics has announced that the final part of a Phase 1 study of its AGMB-447 inhaled ALK5 inhibitor, which enrolled patients with idiopathic pulmonary fibrosis, demonstrated “a generally favorable safety and tolerability profile” in… [Read more . . .]

• Cystic Fibrosis Foundation to make strategic investment of up to $7.3 million in Ride Therapeutics to support development of inhaled genetic therapies for CF

  The Cystic Fibrosis Foundation has agreed to invest up to $7.3 million in Ride Therapeutics to support identification of potential delivery vehicles for inhaled genetic therapies for CF. According to the CFF, Ride plans to test millions… [Read more . . .]

• FDA clears IND for Nasus’s NS002 epinephrine nasal powder for the treatment of anaphylaxis

  According to Nasus Pharma, the FDA has cleared an IND for a study of Nasus’s NS002 intranasal dry powder epinephrine for the treatment of anaphylaxis. Nasus says that it also plans to initiate a pivotal… [Read more . . .]

• Aptar and MGH partner on development of platform to aid development of nose-to-brain therapies

  Aptar Pharma will provide nasal delivery technology for a project led by Massachusetts General Hospital Assistant Professor Alice Stanton to develop a platform designed to improve development of therapies intended for nose-to-brain delivery. The company… [Read more . . .]

• Hikma announces regulatory submissions for its epinephrine nasal spray in the US, UK, Europe, and Canada

  According to Hikma Pharmaceuticals, regulators in the US, Europe, and the UK have accepted submissions for the company’s epinephrine nasal spray for the treatment of anaphylaxis, and the company has also filed a submission in… [Read more . . .]

• Ethris gets €30 million financing through the European Investment Bank and the EC’s Health Emergency Preparedness and Response Authority for development of inhaled and nasal mRNA vaccines

• Pulmovant says Phase 2 PHocus trial of its mosliciguat DPI met its primary endpoint, Phase 3 PHrontier trial has been initiated

• Glenmark launches Ryaltris olopatadine / mometasone nasal spray in Brazil

• Proveris Scientific names Daniel Tereau as President and CEO

• Leyden Labs reveals that it has acquired RIGImmune and announces results from a Phase 1 trial of RIG-101 intranasal antiviral

More news . . .